Oppenheimer & Co’s Heron Therapeutics HRTX Stock Holding History

Oppenheimer & Co’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,900	Closed	-$231K	–	1472
2020 Q4	$231K	Sell	10,900 -1,900	-15%	-$33K	﹤0.01%	1189
2020 Q3	$190K	Sell	12,800 -2,000	-14%	-$31.2K	﹤0.01%	1167
2020 Q2	$218K	Sell	14,800 -8,000	-35%	-$131K	0.01%	1084
2020 Q1	$268K	Hold	22,800	–	–	0.01%	937
2019 Q4	$536K	Hold	22,800	–	–	0.01%	806
2019 Q3	$422K	Sell	22,800 -1,100	-5%	-$20.2K	0.01%	855
2019 Q2	$444K	Sell	23,900 -8,000	-25%	-$160K	0.01%	861
2019 Q1	$780K	Sell	31,900 -15,526	-33%	-$406K	0.02%	657
2018 Q4	$1.23M	Sell	47,426 -9	-0%	-$247	0.04%	470
2018 Q3	$1.5M	Buy	47,435 +9,520	+25%	+$355K	0.04%	475
2018 Q2	$1.47M	Sell	37,915 -5,984	-14%	-$191K	0.04%	465
2018 Q1	$1.21M	Buy	+43,899	New	+$996K	0.03%	543

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Oppenheimer & Co's HRTX Position: Q1 2021 in Review

Oppenheimer & Co sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 10,900 shares — an estimated $231K sold.

Oppenheimer & Co first reported a position in HRTX in Q1 2018 and held it in 12 quarters. The position peaked at $1.5M in Q3 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Oppenheimer & Co reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Oppenheimer & Co sold 10,900 Heron Therapeutics shares in Q1 2021, an estimated $231K.
Oppenheimer & Co first reported a position in Heron Therapeutics in Q1 2018 and held it in 12 quarters.
Oppenheimer & Co's Heron Therapeutics position peaked at $1.5M in Q3 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Oppenheimer & Co's 13F filing for Q1 2021, filed 10 May 2021.